| Indication |
Phase |
Sample Size |
Study
Design/Services |
| Chronic Constipation |
2 |
300 |
Randomized,
multi-center, double-blind, placebo-controlled,
dose-range-finding study |
| Chronic Constipation |
3 |
600 |
Randomized,
double-blind, placebo-controlled, parallel group study |
| Crohn's Disease |
3 |
1100 |
Randomized,
multi-center, blinded, placebo-controlled study |
| Healthy Subjects (GERD) |
1 |
40 |
Open-label, randomized,
parallel, multiple-dose study |
| Healthy Subjects (GERD) |
1 |
40 |
Randomized,
double-blind, placebo-controlled, sequential, ascending
single-dose study |
| Healthy Subjects (IBS-C and CC) |
1 |
20 |
Randomized, open-label,
two-period, two-sequence, crossover study |
| Healthy Subjects (IBS-C) |
1 |
80 |
Double-blind,
randomized, placebo-controlled, sequential group, ascending
single-dose study |
| IBS with Constipation |
3 |
800 |
Randomized,
double-blind, placebo-controlled, parallel-group study |
| IBS with Constipation |
2 |
400 |
Randomized,
multi-center, double-blind, placebo-controlled,
dose-range-finding, parallel design trial |
| IBS with Constipation or Chronic Constipation |
3 |
1700 |
Open-label,
long-term safety study/
Provided resources for assisting with patient
closure and listing review |
| Ulcerative Colitis |
3 |
800 |
Randomized,
multi-center, blinded, placebo-controlled study |
| Ulcerative Colitits and Crohn's |
3 |
1900 |
Open-label, long-term
safety and efficacy study |
